dc.creatorRodríguez- Pintó, Ignasi
dc.creatorCervera, Ricard
dc.date.accessioned2017-02-07T15:17:08Z
dc.date.accessioned2022-10-20T20:14:39Z
dc.date.available2017-02-07T15:17:08Z
dc.date.available2022-10-20T20:14:39Z
dc.date.created2017-02-07T15:17:08Z
dc.date.issued2016-12
dc.identifier1390-4450
dc.identifierhttp://dspace.ucuenca.edu.ec/handle/123456789/26623
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4595184
dc.description.abstractThe term anti-phospholipid syndrome (APS) “catastrophic” was introduced to define a serious and rapidly progressive form of APS which leads to multi-organ failure. Patients with catastrophic APS have in common: a) a clinical evidence of multiple organ involvement (3 or more organs); b) pathological evidence of occlusion of multiple small vessels (although some patients have also thrombosis of large vessels) and c) confirmation of the presence of anti-phospholipid antibodies (APAs), usually at high titers. Although they represent less than 1% of all patients with APS, they usually found in an urgent medical situation that requires a thorough clinical monitoring and an early and vigorous treatment
dc.languageeng
dc.publisherUniversidad de Cuenca. Facultad de Ciencias Médicas
dc.relation610.5;200434
dc.subjectSindrome Antifosfolipidico
dc.subjectAnticuerpos Antifosfolipidicos
dc.subjectAnticuerpos Anticardiolipina
dc.subjectInhibidor De Coagulacion Del Lupus
dc.subjectInmunoglobulinas Intravenosas
dc.subjectIntercambio Plasmatico
dc.titleSíndrome antifosfolipídico catastrófico
dc.typeArticle


Este ítem pertenece a la siguiente institución